PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 17155677

Observation of B+ --> Lambda c+ Lambda c- K+ and B0 --> Lambda c+ Lambda c- K0 decays.

N Gabyshev·K Abe·I Adachi·H Aihara·Y Asano·V Aulchenko·T Aushev·S Bahinipati·A M Bakich·V Balagura·E Barberio·W Bartel·A Bay·I Bedny·U Bitenc·I Bizjak·A Bondar·A Bozek·M Bracko·T E Browder·A Chen·W T Chen·B G Cheon·R Chistov·Y Choi·A Chuvikov·S Cole·J Dalseno·M Danilov·M Dash·A Drutskoy·S Eidelman·A Garmash·T Gershon·G Gokhroo·B Golob·J Haba·K Hayasaka·H Hayashii·M Hazumi·T Hokuue·Y Hoshi·S Hou·W-S Hou·Y B Hsiung·K Ikado·A Imoto·K Inami·R Itoh·M Iwasaki·Y Iwasaki·J H Kang·T Kawasaki·H R Khan·H Kichimi·S M Kim·S Korpar·P Krokovny·R Kulasiri·C C Kuo·A Kuzmin·Y-J Kwon·G Leder·T Lesiak·S-W Lin·D Liventsev·G Majumder·T Matsumoto·W Mitaroff·K Miyabayashi·H Miyata·Y Miyazaki·R Mizuk·E Nakano·M Nakao·Z Natkaniec·S Nishida·S Ogawa·T Ohshima·T Okabe·S Okuno·S L Olsen·H Ozaki·H Palka·C W Park·K S Park·R Pestotnik·L E Piilonen·Y Sakai·N Sato·N Satoyama·T Schietinger·O Schneider·C Schwanda·R Seidl·K Senyo·M E Sevior·M Shapkin·H Shibuya·A Somov
View original source ↗Export metadata ↓

Abstract

We report the first measurements of the doubly charmed baryonic B decays B --> Lambda c+ Lambda c- K. The B+ --> Lambda c+ Lambda c- K+ decay is observed with a branching fraction of (6.5(-0.9)(+1.0)+/-1.1+/-3.4)x10(-4) and a statistical significance of 15.4sigma. The B0 --> Lambda c+ Lambda c- K0 decay is observed with a branching fraction of (7.9(-2.3)(+2.9)+/-1.2+/-4.1)x10(-4) and a statistical significance of 6.6sigma. The branching fraction errors are statistical, systematic, and the error resulting from the uncertainty of the Lambda c+ --> pK- pi+ decay branching fraction. The analysis is based on 357 fb(-1) of data accumulated at the Upsilon(4S) resonance with the Belle detector at the KEKB asymmetric-energy e+ e- collider.

Explore related subjects

Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N Gabyshev, K Abe, I Adachi, H Aihara, Y Asano, V Aulchenko, T Aushev, S Bahinipati, A M Bakich, V Balagura, E Barberio, W Bartel, A Bay, I Bedny, U Bitenc, I Bizjak, A Bondar, A Bozek, M Bracko, T E Browder, A Chen, W T Chen, B G Cheon, R Chistov, Y Choi, A Chuvikov, S Cole, J Dalseno, M Danilov, M Dash, A Drutskoy, S Eidelman, A Garmash, T Gershon, G Gokhroo, B Golob, J Haba, K Hayasaka, H Hayashii, M Hazumi, T Hokuue, Y Hoshi, S Hou, W-S Hou, Y B Hsiung, K Ikado, A Imoto, K Inami, R Itoh, M Iwasaki, Y Iwasaki, J H Kang, T Kawasaki, H R Khan, H Kichimi, S M Kim, S Korpar, P Krokovny, R Kulasiri, C C Kuo, A Kuzmin, Y-J Kwon, G Leder, T Lesiak, S-W Lin, D Liventsev, G Majumder, T Matsumoto, W Mitaroff, K Miyabayashi, H Miyata, Y Miyazaki, R Mizuk, E Nakano, M Nakao, Z Natkaniec, S Nishida, S Ogawa, T Ohshima, T Okabe, S Okuno, S L Olsen, H Ozaki, H Palka, C W Park, K S Park, R Pestotnik, L E Piilonen, Y Sakai, N Sato, N Satoyama, T Schietinger, O Schneider, C Schwanda, R Seidl, K Senyo, M E Sevior, M Shapkin, H Shibuya, A Somov. 2006-11-17. Observation of B+ --> Lambda c+ Lambda c- K+ and B0 --> Lambda c+ Lambda c- K0 decays.. https://doi.org/10.1103/physrevlett.97.202003

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗